Rectal expulsion device; percutaneous vs. endoscopic ultrasound biopsy

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Last week, Healio provided live coverage of Digestive Disease Week, the largest gathering of experts in gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

During one presentation, researchers reported that a rectal expulsion device may help predict whether patients with chronic constipation will experience improvements with pelvic floor physical therapy. It was the top story in gastroenterology last week.

Source: Adobe Stock

The second top story covered a debate at Digestive Disease Week on the optimal strategy for liver biopsy: percutaneous vs. endoscopic ultrasound.

Read these and more top stories in gastroenterology below:

Rectal expulsion device may predict outcomes in patients with chronic constipation

An investigational, point-of-care rectal expulsion device may help determine whether patients with chronic constipation will improve with pelvic floor physical therapy, according to data presented at Digestive Disease Week 2022. Read more.

Debate: ‘Safety, adequacy, cost’ still favor percutaneous vs. endoscopic ultrasound biopsy

Although percutaneous liver biopsy is still the “gold standard,” advances in techniques and increased use of endoscopic ultrasound-guided biopsy may soon change that dynamic, according to a debate. Read more.

Additional doses of SARS-CoV-2 vaccine heighten antibody response in patients with IBD

Seroconversion rates and antibody response significantly increased after a third dose of SARS-CoV-2 vaccine in patients with inflammatory bowel disease, according to a presenter. Read more.

VIDEO: Oral S1P receptor modulator induces clinical remission in UC

In a Healio video exclusive, Marla C. Dubinsky, MD, discusses results from the ELEVATE UC trials, in which once daily etrasimod induced clinical remission in patients with ulcerative colitis. Read more.

VIDEO: Mirikizumab induces, maintains clinical remission at 1 year in UC patients

Patients with ulcerative colitis who responded to mirikizumab at 12 weeks achieved and maintained clinical remission and improved bowel urgency severity at 1 year in the phase 3 LUCENT-2 study. Read more.

Leave a Comment

Your email address will not be published.